🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📚 There's still time to submit your work to this ESMO IOTECH Special Issue on 'Developments in Cell Therapy', with guest editors: Alena Gros & @sklobuch. For further details, please check out: spkl.io/60164sUYj

Congratulations to our ESMO IOTECH's Editor-in-Chief John Haanen for the 2024 ESMO Lifetime Achievement Award 🏅. Well-deserved distinction, and we are all so delighted! #ESMO24 ESMO - Eur. Oncology

🔖 Latest REVIEW by Olivera & Ignacio Melero + colleagues on 'Regional and intratumoral adoptive T-cell therapy'. Available #OpenAccess 👇 esmoiotech.org/article/S2590-…

📢 Check out this latest original article by van Duin & colleagues - a multicentre study 🇳🇱. 🔬 Investigating association between TIL abundance in pre-tx primary/metastasis & development of severe irAEs in advanced melanoma. Available #OpenAccess 👇 esmoiotech.org/article/S2590-…

#ESMO24: Do not miss the latest #CancerResearch brought to you by the #ESMOAmbassadors & become part of the conversation. 📌 ow.ly/PgWM50Th6Q3

💡 Presenting your work at #ESMO24 in Barcelona 🇪🇸? Looking for a home for your research work? Consider submitting to ESMO IOTECH 👇 🔗 esmoiotech.org

🏅 Congratulations to Immuno-Oncology and Technology Editor in Chief, John Haanen, for receiving the ESMO Lifetime Achievement Award! Your impact on the field of cancer immunotherapy is truly remarkable. #ESMO24

📢 Hear first hand from our Editor-in-Chief Prof John Haanen about ESMO IOTECH - ESMO - Eur. Oncology’s peer-reviewed open-access specialised journal dedicated to publishing advances in immuno-oncology and technology 👇

📢 Check out this latest original article by Yeghaian, Stefano Trebeschi + colleagues 🇳🇱🇨🇭🇩🇰. 🔬 Integrated noninvasive dx for prediction of survival in immunotherapy: Longitudinal CT, blood tests & clinical parameters ▶️ AI models. Available #OpenAccess 👇 esmoiotech.org/article/S2590-…

📢 Check out this latest original article by Tanja de Gruijl & team Amsterdam UMC. 🧫An organotypic human melanoma-in-skin model as an in vitro tool for testing Vγ9Vδ2-T cell-based immunotherapy. Available #OpenAccess 👇 esmoiotech.org/article/S2590-…

Discover what's in store for Immuno-Oncology and Technology! Watch our video to learn about our article types, the submission process, and what you can expect as an author or reader. Find out more spkl.io/6018fOAbi ESMO IOTECH

.Ton Schumacher Lab was bestowed the 2024 ESMO Award for Immuno-Oncology. He will deliver his award lecture on Wednesday, 11 December 2024 at the opening session of #ESMOImmuno24. 📌ow.ly/FiiN50U0iab

📢 Check out this special case report by Monberg, Svane & colleagues CCIT-DK: National Center for Cancer Immune Therapy University of Helsinki Rigshospitalet 🇩🇰🇫🇮. 💉Combined treatment with TILs + oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma. Available #OpenAccess 👇esmoiotech.org/article/S2590-…

📢 Check out this original article by Konïg & colleagues University of Basel UniSpitalBaselCH 🇨🇭. 💉 BaseTIL trial: A single-center investigator-initiated phase I study of TILs + nivolumab in patients with advanced melanoma. Available #OpenAccess 👇 esmoiotech.org/article/S2590-…

#ESMOImmuno24: Real-world evidence has a place in #CancerImmunotherapy. However, some challenges still limit its implementation in #ClinicalPractice. #ESMODailyReporter #ESMO-GROW Marco Donia 📌ow.ly/rwXC50UoUCo

Welcome to Geneva 🇨🇭 for the much awaited #ESMOImmuno24! 💡 Presenting your work at #ESMOImmuno24? Looking for a home for your research work? Consider submitting to ESMO IOTECH: 🔗 esmoiotech.org

It's finally here! #ESMOImmuno24 📚 Delighted that all accepted abstracts, including late-breaking abstracts, will be published online in the 'ESMO Immuno-Oncology Congress 2024 Abstract Book', a supplement to ESMO IOTECH.

Check out our collection of recently published papers from ESMO’s premier journals, reflecting the themes of the ESMO Immuno-Oncology 2024 congress! Dive into the latest advancements in immunotherapy. spkl.io/6017fwk1l #ESMOImmuno24

#ESMOImmuno24: According to the 2024 ESMO Immuno-Oncology Awardee, Ton Schumacher Lab, tackling the T-cell receptor challenge w/ vast datasets and cutting-edge high-throughput methods may pave the way for advances in #immunotherapy. #ESMODailyReporter 📌ow.ly/rZUO50Up0BE

The impact of #GutMicrobiota on #immunotherapy response and resistance has been established, but studies presented at #ESMOImmuno24 highlight important associations between microbiota and immunotherapy-related toxicities.  #ESMODailyReporter 📌ow.ly/SPtC50Up9u8